Navigation Links
Patient Safety in Challenging Economic Times is Focus of NPSF Annual Congress on May 20-22
Date:1/13/2009

BOSTON, Jan. 13 /PRNewswire/ -- Responding to the increased risk to patient safety in an economic downturn, the National Patient Safety Foundation has announced that the 2009 NPSF Patient Safety Congress will directly address this issue through an extensive program of educational sessions designed to provide attendees with the new thinking and tools critical to keeping patients safe.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO)

This highly acclaimed annual event, to be held May 20-22 at the Gaylord National outside Washington, DC, boasts over 35 individual sessions targeting seven core areas essential to patient safety. In addition, insightful and inspiring plenaries are planned, including a town hall meeting with authors of the pivotal Institute of Medicine report "To Err Is Human" and distinguished members of the Lucian Leape Institute. Intensive full-day pre-Congress programs will also be offered, highlighted by a unique executive-level event providing case studies and discussion focused on successfully building a safety framework, setting safety and quality priorities, and ensuring critical physician engagement. Plus, the NPSF Congress provides direct access to a wide array of innovative solutions providers.

"These times demand increased vigilance from us all," explained Diane Pinakiewicz, President of the National Patient Safety Foundation, "and, as adversity threatens, it also sparks creativity and unique problem-solving, a mindset that is at the very heart of this year's Congress."

Widely recognized as the definitive patient safety event each year, the 2009 NPSF Congress will provide the new learnings, practical tools, and innovative solutions essential to keeping patients safe during these challenging times, and will offer unparalleled opportunities for attendees to
'/>"/>

SOURCE National Patient Safety Foundation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
7. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
8. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
9. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
10. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
11. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Texas (PRWEB) March 26, 2015 ReliantHeart, ... technologies, and Transonic, a supplier of precision transit-time flow ... that will greatly improve the efficiency of the ... enable LVAD patients to experience greater mobility and peace ... with the miniature flow board, will draw 1/6th of ...
(Date:3/26/2015)... WriteResult, a premier provider of ePRO technologies ... School of Public Health and New Haven Farms to ... month-long project. The goal of the study was to ... free access to fresh produce and nutrition education on ... high blood pressure, diabetes and weight gain. Patients completed ...
(Date:3/25/2015)... March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... a result of recent discussions with certain shareholders representing ... the Company, after dealing with certain matters including the ... of shareholders on March 26, 2015 (the "Meeting") it ... of directors will take place when the Meeting reconvenes. ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 /PRNewswire/ ... has commenced Factual Stock Report coverage on ... Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty ... subsidiaries of cultivating, licensing and marketing proprietary ingredients, ... medicinal markets in North America ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... , HIGHLIGHTS: 2008 Results (all percentage comparisons are to comparable ... Sales Gain: Q3 2008 sales increased 7.4% to ... of 4.3%. Q3 organic sales growth of 7.0% for the Company,s ... for the first six months of 2008. ...
... of world-renowned,scientists today announced the launch of Archer ... technologies for the identification of,novel treatments for Alzheimer,s ... Executive Officer Michael,Mullan, M.B.B.S., Ph.D. and Chief Technical ... groundbreaking research that their team has been,conducting in ...
... 21 Canary Foundation, a,nonprofit organization that funds research ... Dr. Sanjiv Sam Gambhir, has,been elected as a new ... This is one of the highest honors in the ... by the National Academy of,Sciences, serves as adviser to ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 3Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 4Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 5Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 6Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 7Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 8Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 9Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 10Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 11Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 12Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 13Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 14Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 15Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 16Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 17Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 18Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 19Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 20New Pharmaceutical Company to Target Alzheimer's Disease 2Canary Foundation's Dr. Sanjiv Sam Gambhir Elected to the National Academies Institute of Medicine 2
(Date:3/12/2015)... IriTech, a leading iris based identity management ... Instruments Design Network, announced today that the Chief Minister ... USB MK2120U device during a launching event of Andhra ... The iris scanner is manufactured by U.S. ... India through its Indian partner, Biometronic ...
(Date:3/12/2015)... March 12, 2015 WHEN:Tuesday, March 17, 2015 ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must ... in several different markets and industries. This is ... an uptrend. Join Frost & ...
(Date:3/10/2015)... 10, 2015  Continuing its 167-year history of offering ... introduces The Eye Scanning Password Authenticator , a ... to secure websites or sensitive data. Employing ... international borders, the device has a small camera that ... the iris, converting them into an encrypted ID that ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... and director of the Walter and Eliza Hall Institute, ... of the Seymour & Vivian Milstein Award for Excellence ... be presented with the award today in Florence, Italy, ... Society and the International Society for Interferon and Cytokine ...
... looking for one thing and finding another. Such was the ... at Northern Arizona University witnessed a small amphibious fish, the ... a small net and back into the water. ... a trout that,s just been landed. The rivulus seemed to ...
... Today in Washington, D.C., Secretary of the Interior ... has been chosen to lead a consortium of seven ... Climate Science Center through a five-year, $7.5 million grant. ... studying the effects of climate change on ecosystems, wildlife, ...
Cached Biology News:Professor Doug Hilton wins Milstein Award for cytokine research 2Aquatic fish jump into picture of evolutionary land invasion 2Aquatic fish jump into picture of evolutionary land invasion 3UMass Amherst wins major grant to host $7.5 million Northeast Climate Science Center 2UMass Amherst wins major grant to host $7.5 million Northeast Climate Science Center 3
... stain is used to distinguish collagen from ... Staining System. The Trichrome stain is often ... muscle and to identify an increase in ... stain, muscle is stained red, collagen - ...
... Morris Water MazeRecords animal movements in a ... subjects at once in a predefined sequence of ... instruments all built around a video camera, frame ... track two fields at once and up to ...
... plus software to note when an animal is ... and trigger a penaltyThe Spatial Behavior line is ... video camera, frame grabber, and feature extraction software ... and up to 6 moving animals. Software ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
Biology Products: